The global drug screening market is projected to reach USD 11.6 billion by 2026, from USD 5.3 billion in 2021, at a CAGR of 16.8% during the forecast period. Growth in this market is attributed to the growing drug & alcohol consumption and the enforcement of stringent laws mandating drug & alcohol testing, rising regulatory approvals for drug screening products & services.
Get Access to Sample Pages + Covid-19 impact analysis: https://www.marketsandmarkets.com/requestsampleNew.asp?id=162987773
Key Market Players
The drug screening market is highly competitive and populated by several big and small players. Prominent players offering drug screening products and services include LabCorp (US), Quest Diagnostics (US), Abbott Laboratories (US), Thermo Fisher Scientific, Inc. (US), Alfa Scientific Designs, Inc. (US), OraSure Technologies, Inc. (US), Siemens Healthineers (Germany), Roche (Switzerland), MPD Inc. (US), Shimadzu (Japan), LifeLoc Technologies (US), Drägerwerk (Germany), Premier Biotech, Inc. (US), Omega Laboratories, Inc. (US), Psychemedics (US), Clinical Reference Laboratory (US), American Bio Medica Corporation (US), ACM Global Laboratories (US), CareHealth America Corp (US), Sciteck, Inc. (US), Synens (France), Intoximeters (US), AccuSource (US), Cordant Health Solutions (US), Millennium Health (US).
LabCorp (US): LabCorp is a leading player in the US drug screening services market. The company’s leading position is attributed to its wide drug testing portfolio, including over 4,800 tests. The company has a strong brand name and robust service portfolio, which provides drug screening services to managed care organizations, governmental agencies, healthcare providers, hospitals and health systems, employers, patients, consumers, contract research organizations, food and nutritional companies, and independent clinical laboratories.
Abbott Laboratories (US): Abbott Laboratories has a strong product portfolio, and its FDA and CE Mark-approved products have helped the company enhance its presence in the drug screening market. Abbott provides abuse testing products and services for many settings such as hospitals, physician offices, criminal justice agencies, workplaces, rehabilitation centers, occupational health clinics, and homes. The company has a strong presence in the US and seeks to enhance its geographical presence by strengthening its business operations in emerging markets such as India and China.
For In-Depth Competitive Analysis, Read a Report: @ https://www.marketsandmarkets.com/Market-Reports/drug-alcohol-screening-market-162987773.html
North America to dominate the drug screening market
North America is expected to dominate the market with a share of 48.2%, followed by Europe. The large share of this geographical segment is attributed to factors such as growing consumption of illicit drugs, the availability of government funding to curb drug abuse, laws supporting drug screening, the growing burden of accidents due to alcohol impairment, and the presence of key players in the region are driving the growth of the drug screening market in this region.
Recent Developments
- Quest Diagnostics and Select Health of South Carolina entered into an agreement to expand Select Health’s laboratory network for its Medicaid and Medicare-Medicaid dual-eligible enrollees and to enhance access to diagnostics information services for members.
- LabCorp Entered into a multi-year agreement with Infirmary Health (US) to offer laboratory testing services in the eastern Gulf Coast.
- Psychemedics introduced a vaping panel test that detects the ingestion of marijuana, CBD, and nicotine drugs by all methods, including electronic cigarettes or smoking
Direct Purchase the report @ https://www.marketsandmarkets.com/Purchase/purchase_reportNew.asp?id=162987773
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
